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Cerebral deposits of iliA4 amyloid protein is a pathologic sign of Alzheimer's disease. A synthetic partial-length (I 28) peptide of this protein 
contains one glutamine and two lysine residues. Here we show that this peptide can be a substrate oftransglutaminase, which catalyzes cross-linking 
between glutamine and lysine residues in peptides, by demonstrating the formation of multimeric peptides due to the action of this enzyme. A
modified (Lys 2s to L-norleucine) version of the synthetic peptide was also cross-linked, but another modified version (Lys ~6 to L-norleucine) was 
very poorly cross-linked, indicating that Lys 16 is involved exclusively in the cross-linking of the partial-length peptide catalyzed by transglutaminase. 
Transglutaminase; Amyloid beta-protein; Alzheimer's disease. 
1. INTRODUCTION 
Alzheimer's disease is characterized by extracellular 
deposits in the brain of insoluble aggregates of amyloid 
proteins [1]. The main component of the deposits is a 
4-kDa fl/A4 amyloid protein [2,3]. This protein arises 
from proteolytic leavage of one or more large trans- 
membrane proteins, the fl/A4 amyloid protein precur- 
sor(s) [4-6]. The cerebral deposits of fl/A4 amyloid 
protein seem to contribute to the pathogenesis of 
Alzheimer's disease [7]. The mechanism of extracellular 
accumulation of this protein is unknown. Amyloid de- 
posits consist of fibers 4 to 10 nm in diameter. The fl/A4 
amyloid protein in amyloid fibrils is organized into a 
cross-fl conformation i which the peptide backbone is 
perpendicular to the fiber axis [8]. Studies using syn- 
thetic peptides containing partial- and full-length se- 
quences of fl/A4 amyloid protein have suggested that 
the physical properties of fl/A4 amyloid protein them- 
selves are the causes of amyloid fibril assembly and the 
formation of insoluble aggregates [9-14]. 
Transglutaminases (protein-glutamine:amine y-glu- 
tamyltransferase, EC 2.3~2.13) are Ca2+-dependent en- 
zymes that catalyze the formation of e-(y-glu- 
tamyl)lysine cross-links between glutamine and lysine 
residues of certain proteins and are involved in several 
biological functions (for review, see [15-17]). These 
functions include blood clotting, wound healing, kerati- 
nization of the epidermis, and stiffening of erythrocyte 
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membranes, in which substrate proteins are cross-linked 
into polymers of high molecular weight hat are insolu- 
ble in denaturants and resistant to proteinases. Selkoe 
et al. [18,19] have characterized the transglutaminase 
activity in the human brain and suggested that transglu- 
taminase is involved in the intracellular formation of 
helically wound intermediate filaments that make up the 
neurofibrillary tangles found in Alzheimer's disease. 
The possibility that transglutaminase i  involved in the 
extracellular formation of the insoluble amyloid depos- 
its has not been examined. Here we report intermolecu- 
lar cross-linking of a synthetic partial-length (1-28) 
peptide of the Alzheimer fl/A4 amyloid protein by 
transglutaminase in vitro and suggest hat this enzyme 
is involved in the formation of the deposits. 
2. MATERIALS AND METHODS 
The following materials were obtained from the sources indicated: 
partial-length (1 28) peptide offl/A4 amyloid protein (Bachem); mod- 
ified partial-length (1-28) peptides of iliA4 amyloid protein (KI6nL 
and K28nL) in which Lys ~6 or Lys 2~ was replaced by L-norleucine 
(lwaki Glass); gel plates for gradient SDS-PAGE (Daiichi Pure Chem- 
icals); and molecular mass marker proteins, LMW (Pharmacia). 
Transglutaminase was purified from a homogenate of guinea pig liver 
on an immunoadsorbent column as described previously [20]. The 
reaction mixture for the cross-linking of peptides contained 40 mM 
Tris-HCl, pH 7.5, 5 mM CaCI2, 10 mM dithiothreitol, 50 ~g/ml 
transglutaminase, and 0.9 mg/ml peptide as the substrate. The reaction 
took place at 37°C and was ended by the addition of a 1/10 volume 
of 0.4 M EDTA. Before SDS-PAGE, control peptides dissolved in 10 
mM Tris-HCI, pH 7.5, and mixtures in which the reaction had been 
stopped were mixed with an equal volume of 2 × sample buffer by the 
method of Laemmli [21] and immersed in boiling water for 1.5 min. 
SDS-PAGE was done with an SDS-polyacrylamide gradient (15 to 
20%) gel and electrode buffer as in the method of Laemmli. The gel 
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Fig. 1. SDS-PAGE pattern of partial-length (1 28) peptide during 
transglutaminase treatment. Lane 1, molecular mass marker proteins 
(from top, phosphorylase b, bovine serum albumin, ovalbumin, car- 
bonic anhydrase, soybean trypsin inhibitor, and a-lactoglobulin; um- 
bers on the left show the molecular masses of these marker proteins). 
Lanes 2 to 5 each contained 3.6/~g of the peptide. Lane 2, partial- 
length (1 28) peptide; lane 3, peptide incubated with transglutaminase 
for 180 min in the presence of 36 mM EDTA; lanes 4 and 5, peptide 
treated with transglutaminase for 20 and 180 rain, respectively. 'M' 
indicates the position of the monomer peptide band and 'TG' indicates 
the position of the transglutaminase band. 
was stained with a solution containing 0.2% Coomassie brilliant blue, 
40% methanol, and 10% acetic acid and destained in 7% acetic acid. 
3. RESULTS AND DISCUSSION 
whether the peptide is present in the high molecular 
weight components. 
Multimer peptides are produced probably by the for- 
mation of  an intermolecular isopeptide bond between 
Gln 15 and either Lys 16 or Lys 2s. For identification of 
which lysine residue was involved in the cross-linking 
catalyzed by transglutaminase, two modified partial- 
length peptides, K16nL and K28nL, were compared for 
their efficiency as substrates for transglutaminase; Lys 16 
or Lys 2s, respectively, was replaced by L-norleucine. The 
cross-linked products of  the modified peptides were an- 
alyzed by SDS-PAGE (Fig. 2). The K28nL peptide 
(lanes 10 and 11) was cross-linked to multimers with a 
reactivity similar to that of  the original partial-length 
peptide (lane 3), but the K16nL peptide (lanes 6 and 7) 
was a poor substrate. Lys ~6 more often participated in 
the transglutaminase-catalyzed cross-linking of  the par- 
tial-length peptide. The reaction products from K16nL 
(lanes 6 and 7) and K28nL (lanes 10 and 11) peptides 
gave a band with faster mobility than that of  the mono- 
mer band, but the reason for the appearance of the new 
band with faster mobility is not known. 
Transglutaminase and fllA4 amyloid protein are 
likely to be present ogether in extracellular sites in the 
brain, because transglutaminase activity has been de- 
tected on the outside surface of  rat brain synaptosomes 
[22]. For more evidence of  our suggestion that transglu- 
taminase is involved in the formation of  the insoluble 
amyloid deposits found in Alzheimer's disease, it would 
be necessary to show that there is an e-(7-glu- 
tamyl)lysine isopeptide bond in the deposits. The iliA4 
The partial-length peptide (1-28; DAEFRHDS-  
GYEVHHQKLVFFAEDVGSNK)  of  the Alzheimer fl/ 
A4 amyloid protein contains a glutamine residue at po- 
sition 15 and lysine residues at positions 16 and 28. For 
detection of  intermolecular cross-links formed by 
transglutaminase between partial-length peptides, 
changes in the molecular size of peptides incubated with 
transglutaminase were analyzed by gradient (15 25%) 
SDS-PAGE (Fig. 1). Incubation for 20 or 180 rain 
caused the disappearance of more than half of  the mon- 
omer peptide, and new bands with slower electro- 
phoretic mobilities appropriate for multimer peptides 
appeared (lanes 4 and 5). Animal transglutaminases 
need calcium ions as a cofactor. In the presence of 
EDTA, multimer peptides were not produced, and the 
monomer peptide remained unchanged (lane 3). These 
results indicate that cross-linking between the peptides 
was caused by transglutaminase. A few components of  
high molecular weight that did not move through the gel 
were detected in the products of  20- and 180-rain reac- 
tions (lanes 4 and 5). These components eemed to be 
polymerized transglutaminase, because the monomeric 
transglutaminase band became fainter as the incubation 
time increased. Further studies are needed to determine 
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Fig. 2. SDS-PAGE pattern of modified partial-length peptides during 
transglutaminase treatment. Lane 1, molecular mass marker proteins 
(see legend of Fig. 1). Lanes 2 to 11 each contained 3.6 ,ug of the 
peptide. Lanes 2 and 3, partial-length (1 28) peptide treated with 
transglutaminase for 0 and 180 min, respectively; ane 4, K16nL pep- 
tide; lanes 5-7, K 16nL peptide treated with transglutaminase for 0, 20, 
and 180 min, respectively; ane 8, K28nL peptide; lanes 9 11, K28nL 
peptide treated with transglutaminase for 0, 20, and 180 min, respec- 
tively. For 'M' and 'TG', see the legend of Fig. 1. 
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protein is produced in soluble form both in vitro and in 
vivo during normal  cellular metabol ism [23-25]. For  
understanding of  the pathological  processes in Alz- 
heimer's disease, the mechanism by which the soluble 
fl/A4 protein is converted to the insoluble form must be 
identified. 
In hereditary cerebral hemorrhage with amyloidosis 
of  the Dutch type, subjects develop deposits of  fl/A4 
amylo id protein around meningeal and cerebral b lood 
vessels. Two patients with this disease were found to 
have a point  mutat ion resulting in the replacement of  
glutamic acid by glutamine at posit ion 22 of  the fl/A4 
amyloid protein [26]. This mutat ion may make the fl/A4 
protein a better substrate for transglutaminase by in- 
creasing the number of  glutamine residues, leading to 
intermolecular cross- l inking that facil itates the forma- 
tion of  amylo id deposits. 
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